X hits on this document





31 / 34

  • 48.

    Gross C , Andersen MS, Krumholz HM, McAvay GJ, Proc- tor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296:2815–2822.

  • 49.

    Robertson RH, Burkhardt JH, Powell M , Eloubeidi MA, Pisu M, Weissman NW. Trends in colon cancer screening procedures in the U.S. Medicare and Tricare populations: 1999–2001. Prev Med. 2006;42:460–462.

  • 50.

    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371.

  • 51.

    Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and ration- ale–update based on new evidence. Gastroenterology. 2003; 124:544–560.

  • 52.

    Phillips KA, Liang SY, Ladabaum U, et al. Trends in colo- noscopy for colorectal cancer screening. Med Care. 2007; 45:160–167.

  • 53.

    Jemal A, Ward E, Thun MJ. Contemporary lung cancer trends among U.S. women. Cancer Epidemiol Biomarkers Prev. 2005;14:582–585.

  • 54.

    Jemal A, Travis WD, Tarone RE, Travis L, Devesa SS. Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type. Int J Cancer. 2003;105:101–107.

  • 55.

    Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004 [Based on November 2006 SEER data submission; posted to the SEER web site, 2007]. Bethesda, Md: National Cancer Institute, 2006. Available at URL: http://seer.cancer.gov/csr/1975_2004/ Accessed April 13,


  • 56.

    Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15:237–241.

  • 57.

    Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the ‘‘PSA ERA.’’ Int J Cancer. 2001;92:893–898.

  • 58.

    Barry MJ. Clinical practice. Prostate-specific-antigen test- ing for early diagnosis of prostate cancer. N Engl J Med. 2001;344:1373–1377.

  • 59.

    Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917–929.

  • 60.

    Shaw PA, Etzioni R, Zeliadt SB, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160:1059–1069.

  • 61.

    Feuer EJ, Mariotto A, Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer. 2002;95:870–880.

  • 62.

    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788.

  • 63.

    Demers RY, Tiwari A, Wei J, Weiss LK, Severson RK, Mon- tie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001;92:2309–2317.

  • 64.

    Seidenfeld J, Samson DJ, Aronson N, et al. Relative effective- ness and cost-effectiveness of methods of androgen suppres- sion in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999;4:i–x,1–246,I1–36, passim.

Report to the Nation, 19752004/Espey et al.


  • 65.

    Bolla M, Gonzalez D, Warde , et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337: 295–300.

  • 66.

    Platz EA, Leitzmann M , Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006;98:1819–1825.

  • 67.

    Centers for Disease Control and Prevention (CDC). Use of Mammograms Among Women Aged > 40 Years—United States, 2000–2005. MMWR Morb Moral Weekly Rep. 2007; 56:49–51.

  • 68.

    Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among

    • U.

      S. women. Breast Cancer Res. 2007;9:R28.

  • 69.

    Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–1674.

  • 70.

    Breen N, Cronin KA, Meissner HI, et al. Reported drop in mammography: is this cause for concern? Cancer. 2007;109: 2405–2409.

  • 71.

    Stewart SL, Sabatino SL, Foster SL, Richardson LC. Decline in breast cancer incidence rates in the United States, 1999–

      • 2003.

        Morb Mortal Wkly Rep. 2007;56:549–553.

  • 72.

    Swan J, Breen N, Burhansstipanov L, et al. Cancer screen- ing and risk factor rates among American Indians. Am J Public Health. 2006;96:340–350.

  • 73.

    Mokbel K. Contemporary treatment of ductal carcinoma in situ of the breast. Med Sci Monitor. 2005;11:RA86–RA93.

  • 74.

    Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369:1703–1710.

  • 75.

    Bray , Loos AH, Tognazzo S, La Vecchia C. Ovarian can- cer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. Int J Cancer. 2005;113: 977–990.

  • 76.

    Gnagy S, Ming EE, Devesa SS, Hartge , Whittemore AS. Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology. 2000;11: 102–105.

  • 77.

    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–1334.

  • 78.

    Jayson M, Sanders H. Increased incidence of serendipi- tously discovered renal cell carcinoma. Urology. 1998;51: 203–205.

  • 79.

    Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002;94:2015–2023.

  • 80.

    Clarke CA, Glaser SL. Epidemiologic trends in HIV-asso- ciated lymphomas. Curr Opin Oncol. 2001;13:354–359.

  • 81.

    Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lym- phoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006;15:630–638.

  • 82.

    Morton LM, Wang SS, Devesa SS, Hartge , Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107: 265–276.

  • 83.

    Davies L, Welch HG. Increasing incidence of thyroid can- cer in the United States, 1973–2002. JAMA. 2006;295:2164–


2167. Jemal A, Devesa SS, Hartge , Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678–683.

Document info
Document views115
Page views115
Page last viewedFri Jan 20 14:30:03 UTC 2017